Laura Négrier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Négrier has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Bertrand Décaudin
ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Université de Lille, F-59000 Lille, France
5 shared publications - Anthony Martin Mena
CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France
4 shared publications - Pascal Odou
CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France
4 shared publications Pascal Odou
3 shared publications- Stéphanie Genay
Univ. Lille, CHU Lille, ULR 7365—GRITA—Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France
3 shared publications Anthony Martin Mena
Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Elsevier in SSRN Electronic Journal
Use of a continuous flow cell culture system to model cytotoxicity during vancomycin IV administration
The low viability rate associated with static incubation of endothelial cells with vancomycin in 96-well plates means that alternative methods are needed to model the toxicity of infused vancomycin. The channel cell culture system enables uniform cell distribution and exposure to drugs under flow conditions. The objective of the present study was to compare the survival of human umbilical vein endothelial cells cultured in the cell culture channel system vs. a 96-well plate, in order to simulate the multi-infusion administration currently recommended for clinical practice. Furthermore, the changes over time in vancomycin concentrations were studied with various protocols under static and flow conditions. Cell survival was higher in the slides designed for flow applications - particularly with the maintenance dose level of vancomycin. In line with the literature data, the main factor in poor cell survival loss was the vancomycin concentration. Thanks to a larger cell surface area, continuous drug administration, and consideration of possible shear stress caused by liquid flow, the cell culture channel system provides cytotoxicity results that are more representative of clinical reality. The higher cell survival rate in the channel cell culture system makes it possible to detect toxicity factors that would probably not be apparent in static incubation conditions. Our results highlight the importance of using appropriate, modified assay techniques to evaluate the cytotoxicity of intravenous drug administration.
- 3 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUse of a continuous flow cell culture system to model cytotoxicity during vancomycin IV administration
The low viability rate associated with static incubation of endothelial cells with vancomycin in 96-well plates means that alternative methods are needed to model the toxicity of infused vancomycin. The channel cell culture system enables uniform cell distribution and exposure to drugs under flow conditions. The objective of the present study was to compare the survival of human umbilical vein endothelial cells cultured in the cell culture channel system vs. a 96-well plate, in order to simulate the multi-infusion administration currently recommended for clinical practice. Furthermore, the changes over time in vancomycin concentrations were studied with various protocols under static and flow conditions. Cell survival was higher in the slides designed for flow applications - particularly with the maintenance dose level of vancomycin. In line with the literature data, the main factor in poor cell survival loss was the vancomycin concentration. Thanks to a larger cell surface area, continuous drug administration, and consideration of possible shear stress caused by liquid flow, the cell culture channel system provides cytotoxicity results that are more representative of clinical reality. The higher cell survival rate in the channel cell culture system makes it possible to detect toxicity factors that would probably not be apparent in static incubation conditions. Our results highlight the importance of using appropriate, modified assay techniques to evaluate the cytotoxicity of intravenous drug administration.
- Open Access
- 17 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (9) , 1222
Evaluation of the Impact of Infusion Set Design on the Particulate Load Induced by Vancomycin–Piperacillin/Tazobactam Incompatibility
Introduction: Drug incompatibilities are among the most common medication errors in intensive care units. A precipitate can form and block the catheter or cause an adverse event in the patient. Intensive care units have implemented various strategies for limiting the occurrence of these incompatibilities, which have already been studied in vitro under standardized conditions. The objective of the present in vitro study was to continue these assessments by determining the impact of the infusion line geometry and the drugs’ position in the infusion set-up on the prevention of vancomycin–piperacillin/tazobactam incompatibility. Methods: Infusion lines with a different common volume, a multilumen medical infusion device, a dilute vancomycin solution, and separate infusions of incompatible drugs were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. Results: Reducing the common volume, using multilumen medical devices, or spacing out the two incompatible drugs on the infusion line did not prevent the occurrence of a significant particulate load. Only dilution of the vancomycin solution was associated with a significantly lower particulate load and the absence of drug incompatibility. Conclusions: Our results show that under specific conditions, it is possible to reduce particulate contamination considerably.
- 17 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (9) , 1222
Open AccessEvaluation of the Impact of Infusion Set Design on the Particulate Load Induced by Vancomycin–Piperacillin/Tazobactam Incompatibility
Introduction: Drug incompatibilities are among the most common medication errors in intensive care units. A precipitate can form and block the catheter or cause an adverse event in the patient. Intensive care units have implemented various strategies for limiting the occurrence of these incompatibilities, which have already been studied in vitro under standardized conditions. The objective of the present in vitro study was to continue these assessments by determining the impact of the infusion line geometry and the drugs’ position in the infusion set-up on the prevention of vancomycin–piperacillin/tazobactam incompatibility. Methods: Infusion lines with a different common volume, a multilumen medical infusion device, a dilute vancomycin solution, and separate infusions of incompatible drugs were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. Results: Reducing the common volume, using multilumen medical devices, or spacing out the two incompatible drugs on the infusion line did not prevent the occurrence of a significant particulate load. Only dilution of the vancomycin solution was associated with a significantly lower particulate load and the absence of drug incompatibility. Conclusions: Our results show that under specific conditions, it is possible to reduce particulate contamination considerably.
- Open Access
- 19 August 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (8) , 1085
The Infusion of Piperacillin/Tazobactam with an Elastomeric Device: A Combined 24-H Stability Study and Drug Solution Flow Rate Analysis
Bacterial respiratory tract infections (e.g., in patients with cystic fibrosis) may be treated with the intravenous infusion of a piperacillin/tazobactam (P/T) solution through an elastomeric device. In the present work, we combined a 24-h drug stability study with an assessment of the drug solution flow rate during an in vitro simulated infusion. Experiments were performed in triplicate with two excipient-free generic P/T solutions and an excipient-containing proprietary P/T solution in saline (all 50/6.25 mg/mL) released from an elastomeric infusion device at 32 °C. The P/T solutions’ stability was assessed by an HPLC-UV assay, pH and osmolality measurements, a visual assessment, and particle counting. Before these analyses, a forced degradation study was performed. To assess the flow rate, a precision scale was used to weigh the solution collected at the infusion line outlet. The stability criteria were <10% degradation and a flow rate within ± 15% of the nominal value over the 24-h infusion period: all three P/T solutions were found to be stable. The actual flow rate was lower than the expected flow rate; this difference was probably due to the drug solution’s high viscosity and must be taken into account in clinical use.
- 19 August 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (8) , 1085
Open AccessThe Infusion of Piperacillin/Tazobactam with an Elastomeric Device: A Combined 24-H Stability Study and Drug Solution Flow Rate Analysis
Bacterial respiratory tract infections (e.g., in patients with cystic fibrosis) may be treated with the intravenous infusion of a piperacillin/tazobactam (P/T) solution through an elastomeric device. In the present work, we combined a 24-h drug stability study with an assessment of the drug solution flow rate during an in vitro simulated infusion. Experiments were performed in triplicate with two excipient-free generic P/T solutions and an excipient-containing proprietary P/T solution in saline (all 50/6.25 mg/mL) released from an elastomeric infusion device at 32 °C. The P/T solutions’ stability was assessed by an HPLC-UV assay, pH and osmolality measurements, a visual assessment, and particle counting. Before these analyses, a forced degradation study was performed. To assess the flow rate, a precision scale was used to weigh the solution collected at the infusion line outlet. The stability criteria were <10% degradation and a flow rate within ± 15% of the nominal value over the 24-h infusion period: all three P/T solutions were found to be stable. The actual flow rate was lower than the expected flow rate; this difference was probably due to the drug solution’s high viscosity and must be taken into account in clinical use.
- Open Access
- 1 August 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (8) , 2069
Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strategies have never been compared directly (and particularly in terms of the particulate load and drug mass flow rate) under standardized conditions. The objective of the present in vitro study was to evaluate the impact of various strategies for preventing incompatibility between simultaneously infused vancomycin and piperacillin/tazobactam. Methods: An in-line filter, a dilute vancomycin solution (5 mg/mL), and an alternative saline administration line were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. The antibiotic concentration was measured in an HPLC-UV assay. Result: The use of an in-line filter and an alternative saline administration route did not significantly reduce the particulate load caused by vancomycin-piperacillin/tazobactam incompatibility. Dilution of the vancomycin solution was associated with a significantly lower particulate load and maintenance of the vancomycin mass flow rate. Discussion: It is important to systematically compare the efficacy of strategies for preventing drug incompatibility. The use of diluted vancomycin solution gave the best results in the case of vancomycin-piperacillin/tazobactam incompatibility.
- 1 August 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (8) , 2069
Open AccessEvaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strategies have never been compared directly (and particularly in terms of the particulate load and drug mass flow rate) under standardized conditions. The objective of the present in vitro study was to evaluate the impact of various strategies for preventing incompatibility between simultaneously infused vancomycin and piperacillin/tazobactam. Methods: An in-line filter, a dilute vancomycin solution (5 mg/mL), and an alternative saline administration line were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. The antibiotic concentration was measured in an HPLC-UV assay. Result: The use of an in-line filter and an alternative saline administration route did not significantly reduce the particulate load caused by vancomycin-piperacillin/tazobactam incompatibility. Dilution of the vancomycin solution was associated with a significantly lower particulate load and maintenance of the vancomycin mass flow rate. Discussion: It is important to systematically compare the efficacy of strategies for preventing drug incompatibility. The use of diluted vancomycin solution gave the best results in the case of vancomycin-piperacillin/tazobactam incompatibility.
- 25 March 2021
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 77 (9) , 1309-1321
Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review
Purpose Drug protocols in intensive care units may require the concomitant administration of many drugs as patients’ venous accesses are often limited. A major challenge for clinicians is to limit the risk of simultaneously infusing incompatible drugs. Incompatibilities can lead to the formation of particles and inactivation of drugs, whose consequences on the body have already been indicated. Our objective was to assess current strategies to counter the risk of incompatible infusions and control the resulting clinical consequences. Methods This review was independently conducted by three investigators in respect of the PRISMA statement. Three online databases were consulted. Full-text articles, notes, or letters written in English or French, published or in press between the 1990s and the end of February 2020, with clinical study design, were eligible. Parameters of interest were mainly number and size of particles, and a number of observed/avoided incompatibilities. Results All in all, 382 articles were screened, 17 meeting all the acceptance criteria. The strategies outlined and assessed were filtration, the use of multi-lumen devices, the purging of infusion lines, incompatibility tables and databases, and the use of standard operating procedures. Conclusion Although many strategies have been developed in recent years to address drug incompatibility risks, clinical data is still lacking. All studies with in vitro design were excluded although some current innovative strategies, like niosomes, should be considered and studied by means of clinical data in the future.
- 25 March 2021
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 77 (9) , 1309-1321
Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review
Purpose Drug protocols in intensive care units may require the concomitant administration of many drugs as patients’ venous accesses are often limited. A major challenge for clinicians is to limit the risk of simultaneously infusing incompatible drugs. Incompatibilities can lead to the formation of particles and inactivation of drugs, whose consequences on the body have already been indicated. Our objective was to assess current strategies to counter the risk of incompatible infusions and control the resulting clinical consequences. Methods This review was independently conducted by three investigators in respect of the PRISMA statement. Three online databases were consulted. Full-text articles, notes, or letters written in English or French, published or in press between the 1990s and the end of February 2020, with clinical study design, were eligible. Parameters of interest were mainly number and size of particles, and a number of observed/avoided incompatibilities. Results All in all, 382 articles were screened, 17 meeting all the acceptance criteria. The strategies outlined and assessed were filtration, the use of multi-lumen devices, the purging of infusion lines, incompatibility tables and databases, and the use of standard operating procedures. Conclusion Although many strategies have been developed in recent years to address drug incompatibility risks, clinical data is still lacking. All studies with in vitro design were excluded although some current innovative strategies, like niosomes, should be considered and studied by means of clinical data in the future.
- Open Access
- 8 March 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3) , 351
Optimising an Infusion Protocol Containing Cefepime to Limit Particulate Load to Newborns in a Neonatal Intensive Care Unit
Background: In neonatal intensive care units (NICUs), the simultaneous administration of drugs requires complex infusion methods. Such practices can increase the risk of drug incompatibilities resulting in the formation of a particulate load with possible clinical consequences. Methods: This paper evaluates strategies to reduce the particulate load of a protocol commonly used in NICUs with a potential medical incompatibility (vancomycin/cefepime combination). The protocol was reproduced in the laboratory and the infusion line directly connected to a dynamic particle counter to evaluate the particulate matter administered during infusion. A spectrophotometry UV assay of cefepime evaluated the impact of filters on the concentration of cefepime administered. Results: A significant difference was observed between the two infusion line configurations used in the NICU, with higher particulate load for cefepime infused via the emergency route. There was no change in particulate load in the absence of vancomycin. A filter on the emergency route significantly reduced this load without decreasing the cefepime concentration infused. Preparation of cefepime seemed to be a critical issue in the protocol as the solution initially contained a high level of particles. Conclusion: This study demonstrated the impact of a reconstitution method, drug dilution and choice of infusion line configuration on particulate load.
- 8 March 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3) , 351
Open AccessOptimising an Infusion Protocol Containing Cefepime to Limit Particulate Load to Newborns in a Neonatal Intensive Care Unit
Background: In neonatal intensive care units (NICUs), the simultaneous administration of drugs requires complex infusion methods. Such practices can increase the risk of drug incompatibilities resulting in the formation of a particulate load with possible clinical consequences. Methods: This paper evaluates strategies to reduce the particulate load of a protocol commonly used in NICUs with a potential medical incompatibility (vancomycin/cefepime combination). The protocol was reproduced in the laboratory and the infusion line directly connected to a dynamic particle counter to evaluate the particulate matter administered during infusion. A spectrophotometry UV assay of cefepime evaluated the impact of filters on the concentration of cefepime administered. Results: A significant difference was observed between the two infusion line configurations used in the NICU, with higher particulate load for cefepime infused via the emergency route. There was no change in particulate load in the absence of vancomycin. A filter on the emergency route significantly reduced this load without decreasing the cefepime concentration infused. Preparation of cefepime seemed to be a critical issue in the protocol as the solution initially contained a high level of particles. Conclusion: This study demonstrated the impact of a reconstitution method, drug dilution and choice of infusion line configuration on particulate load.